---
title: "Validating Marker Therapeutics’ MAR-T Platform in Pancreatic Cancer: MT-601 Upside Supports Buy Rating and $10 Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271537663.md"
description: "Marker Therapeutics received a Buy rating from analyst Patrick Trucchio of H.C. Wainwright, with a $10 price target. This rating is based on promising Phase 1/2 data showing the effectiveness of its MAR-T cell platform in pancreatic cancer, demonstrating meaningful response rates and durable disease control. The proprietary product MT-601 has cleared FDA IND review for a Phase 1 study. Trucchio's analysis incorporates a risk-adjusted DCF framework, supporting the $10 target while acknowledging potential risks. Canaccord Genuity also maintains a Buy rating with an $8 target."
datetime: "2026-01-05T14:45:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271537663.md)
  - [en](https://longbridge.com/en/news/271537663.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271537663.md)
---

# Validating Marker Therapeutics’ MAR-T Platform in Pancreatic Cancer: MT-601 Upside Supports Buy Rating and $10 Target

Marker Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.

Patrick Trucchio has given his Buy rating due to a combination of factors related to Marker Therapeutics’ MAR-T cell platform and its emerging clinical profile in pancreatic cancer. He highlights newly published Phase 1/2 data from Baylor College of Medicine showing that MAR-T cells, when used with first-line chemotherapy, produced meaningful response rates, durable disease control, and median overall survival that together point to a clinically relevant benefit in a cancer type with few effective options. The study also showed that the infused MAR-T cells persisted in patients for up to a year and that better expansion and persistence were associated with stronger clinical responses, all while maintaining a manageable safety profile and not worsening chemotherapy-related toxicities. In his view, these results support continued development of MAR-T therapy in pancreatic cancer and validate Marker’s strategy to pursue this indication.

Trucchio further underscores the potential of Marker’s proprietary product, MT-601, which is designed to target six tumor-associated antigens, potentially improving tumor cell killing and addressing key resistance mechanisms such as immune evasion and antigen loss. He notes that MT-601 has cleared FDA IND review for a Phase 1 study in combination with frontline chemotherapy in advanced pancreatic cancer, with a trial design that includes lymphodepletion and dose escalation to refine dosing and efficacy signals. He also considers the company’s non-dilutive funding commitments from CPRIT and the NIH as supportive of its clinical plans without materially constraining other pipeline programs. Based on a risk-adjusted DCF and sum-of-the-parts framework that incorporates probabilities of success for MT-601 and other assets, along with a 12% discount rate and a 6x terminal multiple, he arrives at an implied equity value that supports his $10 price target and Buy recommendation, while acknowledging multiple development, competitive, and financing risks.

In another report released on December 23, Canaccord Genuity also maintained a Buy rating on the stock with a $8.00 price target.

### Related Stocks

- [MRKR.US](https://longbridge.com/en/quote/MRKR.US.md)

## Related News & Research

- [13:02 ET/C O R R E C T I O N -- O Positiv Health/](https://longbridge.com/en/news/282726350.md)
- [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md)
- [Pancreatic cancer pill shown to nearly double overall survival time, drug company says](https://longbridge.com/en/news/282687539.md)
- [Revolution Medicines Says Daraxonrasib Shows Improvement In Survival In Late-Stage Pancreatic Cancer Study](https://longbridge.com/en/news/282550417.md)
- [Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 | PALI Stock News](https://longbridge.com/en/news/283003856.md)